Regeneron’s (NASDAQ:REGN) Q2 CY2026: Strong Sales

Biotech company Regeneron (NASDAQ:REGN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 16.7% year on year to $4.29 billion. Its non-GAAP profit of $14.29 per share was 40.1% above analysts’ consensus estimates.

Is now the time to buy Regeneron? Find out by accessing our full research report, it’s free.

Company Overview

Founded by scientists who wanted to build a company where science could thrive, Regeneron Pharmaceuticals (NASDAQ:REGN) develops and commercializes medicines for serious diseases, with key products treating eye conditions, allergic diseases, cancer, and other disorders.

Revenue Growth

A company’s long-term sales performance can indicate its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Unfortunately, Regeneron’s 4.5% annualized revenue growth over the last five years was mediocre. This was below our standard for the healthcare sector and is a rough starting point for our analysis.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Regeneron’s annualized revenue growth of 7.3% over the last two years is above its five-year trend, which is encouraging.

We can dig further into the company’s revenue dynamics by analyzing its most important segments, Collaboration and Product & Pipeline, which are 38.3% and 57.2% of revenue. Over the last two years, Regeneron’s Collaboration revenue averaged 2.6% year-on-year declines. On the other hand, its Product & Pipeline revenue averaged 18.5% growth.

This quarter, Regeneron reported year-on-year revenue growth of 16.7%, and its $4.29 billion of revenue exceeded Wall Street’s estimates by 12.4%.

Looking ahead, sell-side analysts expect revenue to grow 7.3% over the next 12 months, similar to its two-year rate. This projection is above the sector average and suggests its newer products and services will help support its recent top-line performance.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.

Adjusted Operating Margin

Adjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes, and interest on debt - metrics less connected to business fundamentals.

Regeneron has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 40.4%.

Analyzing the trend in its profitability, Regeneron’s adjusted operating margin decreased by 22.9 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 5.4 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.

In Q2, Regeneron generated an adjusted operating margin profit margin of 30.1%, down 7 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Sadly for Regeneron, its EPS declined by 2.6% annually over the last five years while its revenue grew by 4.5%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.

Diving into the nuances of Regeneron’s earnings can give us a better understanding of its performance. As we mentioned earlier, Regeneron’s adjusted operating margin declined by 22.9 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q2, Regeneron reported adjusted EPS of $14.29, up from $12.89 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Regeneron’s full-year EPS to grow 7.3% from $47.03 to $50.45.

Key Takeaways from Regeneron’s Q2 Results

It was good to see Regeneron beat analysts’ EPS expectations this quarter. We were also excited its revenue outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this quarter featured some important positives. The stock traded up 4.7% to $727.79 immediately following the results.

Sure, Regeneron had a solid quarter, but if we look at the bigger picture, is this stock a buy? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).